News

Marseille, France, February 24, 2005 – Ipsogen SAS, the French cancer diagnostics company, announced today that its latest breast cancer program results had been selected for presentation at the EBCC 5 congress, the 5th European Breast Cancer Conference, held in Nice, France, 21-25 March 2006.

The abstract titled “Identification and validation of a genomic predictor to distinguish classes of patients with distinct outcomes among poor prognosis breast tumours after anthracycline-based adjuvant therapy", has been selected by the EBCC-5 Scientific Committee for oral presentation in the session "How should we do phase II/III trials in the age of molecular biology?". The session will be held on Wednesday 22 March 2006 and comprises talks from Invited Speakers along with the best submitted abstracts.